Pulsed Magnetic Field Therapy Cuts Fatigue and Boosts Function in Long COVID Patients

Post-COVID-19 syndrome (PCS) affects millions worldwide, with persistent fatigue as its most debilitating hallmark. Proposed mechanisms include mitochondrial dysfunction, which impairs cellular energy production and may underlie the characteristic post-exertional malaise. Pulsed electromagnetic field (PEMF) therapy has been shown in preclinical work to modulate mitochondrial dynamics and promote angiogenesis, making it a biologically plausible intervention. This pilot study, conducted at the Medical University of Vienna, was designed to assess whether PEMF is feasible, acceptable, and potentially effective for post-COVID fatigue before committing to a larger powered trial.

The study enrolled 20 patients (mean age ~42 years, roughly equal sex distribution) who had confirmed COVID-19 and scored 2–4 on the Post-COVID Functional Status Scale, indicating moderate-to-severe functional limitation. Participants were randomized 1:1 to active PEMF or sham treatment. The active arm used the Papimi Delta device, delivering high-energy pulses (~96 W per pulse, 50–100 mT magnetic flux density, ~240 kHz base frequency) to six body regions per session. Ten 30-minute sessions were administered twice weekly over 5 weeks. Sham applicators were visually and acoustically identical but generated no magnetic field, maintaining patient blinding. Assessments occurred at baseline (T0), post-treatment (T1), and 5-week follow-up (T2).

The intervention group demonstrated a notable improvement in the 6-minute walk test (6MWT), a validated measure of submaximal exercise capacity. Fatigue, the primary symptom of interest, improved on both the Brief Fatigue Inventory (BFI) and the Multidimensional Fatigue Inventory (MFI), which captures general, physical, mental fatigue, reduced activity, and reduced motivation. The Hospital Anxiety and Depression Scale depression subscale improved in the PEMF group, as did the Insomnia Severity Index and the Work Ability Index. Most subscales of the SF-36 health-related quality-of-life questionnaire also showed improvement in the active arm. The placebo group, by contrast, showed minimal change across these measures.

Feasibility and acceptance outcomes were strongly positive for PEMF. There were zero dropouts in the intervention group across all 10 sessions, while three patients dropped out of the placebo group. Adherence was described as very good, and patients in the active arm reported perceiving the treatment as effective. No serious adverse events were reported. These findings are particularly meaningful given that post-COVID patients often struggle with treatment burden and energy-pacing constraints, making a well-tolerated, passive therapy especially attractive.

The study has important limitations that temper interpretation. The sample size of 20 patients is small, and the pilot was not powered for statistical significance on efficacy endpoints — results are descriptive and hypothesis-generating rather than confirmatory. The single-blind design meant treating staff were not blinded due to the different applicator types required. Baseline demographic differences existed between groups (e.g., age IQR was notably wider in the control group). No biomarker data (e.g., mitochondrial function, inflammatory markers) were collected to elucidate mechanism. Nonetheless, the study provides the foundational feasibility and safety data needed to design a properly powered RCT, and the consistency of improvement across multiple validated outcome measures is encouraging for this underserved patient population.